Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.12 USD | -0.30% | +15.09% | +61.18% |
May. 09 | Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Chart calendar Verastem, Inc.
Upcoming events on Verastem, Inc.
Past events on Verastem, Inc.
2024-05-14 03:35 pm | RBC Capital Markets Global Healthcare Conference |
2024-05-09 04:02 pm | Q1 2024 Earnings Release |
2024-04-10 12:00 pm | American Association for Cancer Research Meeting - Abstract #: 7268 |
2024-04-09 12:00 pm | American Association for Cancer Research Meeting - Abstract #: 4745 |
2024-04-09 12:00 pm | American Association for Cancer Research Meeting - Abstract #: 4127 |
2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract #: 3318 |
2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract #: 3318 |
2024-03-18 02:45 pm | Society of Gynecologic Oncology Meeting - Charlotte C |
2024-03-18 02:45 pm | Society of Gynecologic Oncology Meeting - Rachel N |
2024-03-17 07:15 pm | Society of Gynecologic Oncology Meeting |
2024-03-17 04:45 pm | Society of Gynecologic Oncology Meeting |
2024-03-14 04:05 pm | Q4 2023 Earnings Release |
2024-01-18 04:00 pm | B. Riley Securities Oncology Conference |
2024-01-17 09:00 am | Extraordinary Shareholders Meeting |
2023-11-08 04:12 pm | Q3 2023 Earnings Release |
2023-11-04 | International Gynecologic Cancer Society Meeting |
2023-09-26 09:55 am | Cantor Global Healthcare Conference |
2023-09-12 02:00 pm | H.C. Wainwright Global Investment Conference |
2023-08-08 04:05 pm | Q2 2023 Earnings Release |
2023-06-05 02:15 pm | American Society of Clinical Oncology Conference - Abstract #: 5515 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 17,5 16,3 7.23% | 88,5 54,6 62.1% | 2,05 1,47 39.72% | 2,60 2,66 -2.55% | 0,00 0,00 - | 0,20 |
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | -132 -126 -5.32% | -49,4 -30,7 -60.98% | -61,4 -58,0 -5.91% | -72,9 -74,3 1.87% | -92,1 -82,5 -11.66% | -115 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -149 -140 -6.96% | -67,5 -62,3 -8.47% | -71,2 -70,6 -0.86% | -73,8 -75,3 1.97% | -87,4 -82,2 -6.32% | -119 |
Net income Million USD | Released Forecast Spread | -149 -140 -6.96% | -67,7 -62,3 -8.78% | -71,2 -70,6 -0.86% | -73,8 -75,3 1.97% | -87,4 -81,8 -6.75% | -118 |
EPS USD | Released Forecast Spread | -24,0 -22,6 -6.19% | -5,28 -4,86 -8.64% | -4,92 -4,76 -3.36% | -4,56 -4,72 3.39% | -3,96 -3,55 -11.47% | -3,92 |
Announcement Date | 11/03/20 | 18/03/21 | 28/03/22 | 14/03/23 | 14/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 2,60 1,50 73.07% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,02 - | 0,00 0,02 - | 0,00 0,03 - | 0,00 0,00 - | 0,00 0,00 - | 0,06 | 0,06 | 0,11 | 0,80 | 5,50 |
EBIT Million USD | Released Forecast Spread | -17,0 -15,6 -8.79% | -21,4 -20,1 -6.58% | -17,7 -22,0 19.68% | -16,8 -19,2 12.29% | -19,3 -17,8 -8.96% | -20,3 -19,1 -6.12% | -21,3 -20,7 -2.95% | -31,1 -22,0 -41.65% | -28,1 -29,0 3.09% | -28,4 | -29,3 | -30,1 | -30,0 | -26,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -17,0 -15,6 -8.81% | -22,0 -20,3 -8.05% | -18,1 -22,4 19.07% | -16,8 -19,5 13.72% | -15,7 -17,7 11% | -24,3 -20,5 -18.59% | -20,0 -21,6 7.46% | -27,4 -22,0 -24.22% | -33,9 -30,6 -10.62% | -28,4 | -29,6 | -30,5 | -31,0 | -28,0 |
Net income Million USD | Released Forecast Spread | -17,0 -15,6 -8.81% | -22,0 -20,3 -8.05% | -18,1 -22,4 19.07% | -16,8 -19,5 13.72% | -15,7 -17,7 11% | -24,3 -20,5 -18.59% | -20,0 -21,6 7.46% | -27,4 -22,0 -24.22% | -33,9 -30,6 -10.62% | -28,4 | -29,6 | -30,5 | -31,0 | -28,0 |
EPS USD | Released Forecast Spread | -1,08 -0,98 -9.76% | -1,44 -1,32 -9.09% | -1,08 -1,46 26.03% | -0,96 -1,18 18.37% | -0,96 -1,00 4% | -1,37 -1,06 -29.25% | -0,75 -0,90 16.9% | -1,02 -0,81 -25.54% | -1,26 -1,16 -9.09% | -1,00 | -0,98 | -0,92 | -0,79 | -0,71 |
Announcement Date | 09/05/22 | 08/08/22 | 03/11/22 | 14/03/23 | 09/05/23 | 08/08/23 | 08/11/23 | 14/03/24 | 09/05/24 | - | - | - | - | - |
Past sector events for Verastem, Inc.
Today | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-14 | CELCUITY INC.: Q1 2024 Earnings Release |
2024-05-13 | IMMATICS N.V.: Q1 2024 Earnings Release (Projected) |
2024-05-13 | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-13 | PEPTIDREAM INC.: Q1 2024 Earnings Release |
2024-05-13 | NYKODE THERAPEUTICS: Q1 2024 Earnings Release |
2024-05-13 | ABL BIO INC.: Q1 2024 Earnings Release (Projected) |
2024-05-13 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release (Projected) |
2024-05-13 04:01 pm | ALLOGENE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-12 | PHARMAESSENTIA CORPORATION: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- VSTM Stock
- Calendar Verastem, Inc.